Orencia Extension Data Show Two-Year Progression Benefits In RA Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.
You may also be interested in...
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
The rheumatoid arthritis agent is expected to be available by the end of February.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.